J. Apperley

Hematology · 2002–2022

A researcher in the Science corpus: 11 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

• Hematology — 101 citations into it; #59 of 225 by trust here, #57 by citations

Whom J. Apperley trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. M. Baccarani

Who trusts J. Apperley overall

1. M. Baccarani
2. H. Zahreddine
3. Johanna Andrae
4. S. Swerdlow
5. J. Cortes

Papers from J. Apperley's perspective

Ordered by how strongly the researchers J. Apperley trusts endorse each paper. Same corpus, a different order for every researcher.

1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Journal of Clinical Oncology)
2. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. (Cancer Cell)
3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. (The Lancet Oncology)
4. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (Journal of Clinical Oncology)
5. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
6. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (Blood)
7. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase… (Blood)
8. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
9. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. (Blood)
10. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate (Nature Medicine)

Their papers

• Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity (2016) — 815 citations
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022) — 3,492 citations
• Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice (2014) — 283 citations
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) — 1,917 citations
• Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (2010) — 918 citations
• DEFINING THE INTENSITY OF CONDITIONING REGIMENS : working definitions (2009) — 1,682 citations
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009) — 1,280 citations
• Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (2007) — 616 citations
• Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. (2007) — 643 citations
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) — 1,349 citations
• Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. (2002) — 609 citations